These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

62 related items for PubMed ID: 1338741

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Heparin and fibrinolysis--comparison of subcutaneous administration of unfractionated and low molecular weight heparin.
    Eriksson E, Wollter IM, Christenson B, Stigendal L, Risberg B.
    Thromb Haemost; 1988 Apr 08; 59(2):284-8. PubMed ID: 2838926
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Biological activity and safety of the subcutaneous administration of high doses of low molecular weight heparin for 8 days in human volunteers.
    Harenberg J, Giese C, Dempfle CE, Stehle G, Heene DL.
    Thromb Haemost; 1989 Jun 30; 61(3):357-62. PubMed ID: 2552604
    [Abstract] [Full Text] [Related]

  • 5. Comparison of the pharmacokinetic profiles of three low molecular mass heparins--dalteparin, enoxaparin and nadroparin--administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism).
    Collignon F, Frydman A, Caplain H, Ozoux ML, Le Roux Y, Bouthier J, Thébault JJ.
    Thromb Haemost; 1995 Apr 30; 73(4):630-40. PubMed ID: 7495071
    [Abstract] [Full Text] [Related]

  • 6. Chrono-pharmacological study of once daily curative dose of a low molecular weight heparin (200 IU antiXa/kg of Dalteparin) in ten healthy volunteers.
    Mismetti P, Reynaud J, Tardy-Ponce B, Laporte-Simitsidis S, Scully M, Goodwyn C, Queneau P, Decousus H.
    Thromb Haemost; 1995 Aug 30; 74(2):660-6. PubMed ID: 8585003
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The correlation between plasma anti-factor Xa activity and haemostatic tests in healthy dogs, following the administration of a low molecular weight heparin.
    Mischke R, Grebe S.
    Res Vet Sci; 2000 Dec 30; 69(3):241-7. PubMed ID: 11124095
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Bioequivalence of generic and branded subcutaneous enoxaparin: a single-dose, randomized-sequence, open-label, two-period crossover study in healthy Chinese male subjects.
    Feng L, Shen-Tu J, Liu J, Chen J, Wu L, Huang M.
    Clin Ther; 2009 Jul 30; 31(7):1559-67. PubMed ID: 19695405
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin).
    Mismetti P, Laporte-Simitsidis S, Navarro C, Sié P, d'Azemar P, Necciari J, Duret JP, Gaud C, Decousus H, Boneu B.
    Thromb Haemost; 1998 Jun 30; 79(6):1162-5. PubMed ID: 9657442
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Time-course of anti-Xa effects of calcium heparin and low-molecular-weight heparin given s.c.: insights for thrombosis prevention.
    Romeo G, Salanitri G, Catania G.
    Drugs Exp Clin Res; 1988 Jun 30; 14(6):423-7. PubMed ID: 2850903
    [Abstract] [Full Text] [Related]

  • 16. Pharmacodynamics and tolerance of two nadroparin formulations (10,250 and 20,500 anti Xa IU x ml(-1)) delivered for 10 days at therapeutic dose.
    Boneu B, Navarro C, Cambus JP, Caplain H, d'Azemar P, Necciari J, Duret JP, Gaud C, Sié P.
    Thromb Haemost; 1998 Feb 30; 79(2):338-41. PubMed ID: 9493587
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Effect of low molecular weight heparin on coagulation parameters and bleeding time in healthy volunteers.
    Warning A, Nies D, Wolf H, Welzel D.
    Arzneimittelforschung; 1987 Jul 30; 37(7):847-9. PubMed ID: 2823841
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.